Items where authors include "Boleti, E"

Article

Brown, JE, Royle, K-L orcid.org/0000-0003-0225-1199, Gregory, W et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Hall, PE, Shepherd, STC, Brown, J et al. (19 more authors) (2020) Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus, 6 (5). P999-P1005. ISSN 2405-4569

Powles, T, Brown, J, Larkin, J et al. (17 more authors) (2016) A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology, 27 (5). pp. 880-886. ISSN 0923-7534

Powles, T, Wheater, M, Din, O et al. (11 more authors) (2016) A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. European Urology, 69 (3). pp. 450-456. ISSN 0302-2838